<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00711321</url>
  </required_header>
  <id_info>
    <org_study_id>Affiris 004</org_study_id>
    <secondary_id>EudraCT 2008-002764-33</secondary_id>
    <nct_id>NCT00711321</nct_id>
  </id_info>
  <brief_title>Long-term Safety and Tolerability of AFFITOPE AD02</brief_title>
  <official_title>Phase Ib Follow-up Study to Evaluate Long-term Safety and Tolerability of Immunization With AFFITOPE AD02 Applied During AFFiRiS 002</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affiris AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affiris AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term tolerability and -safety of AFFITOPE
      AD02 applied during AFFiRiS 002
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term tolerability</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical and immunological efficacy (evaluated in an explorative manner only)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">23</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>AFFITOPE AD02 with adjuvant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>AFFITOPE AD02 without adjuvant</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects having participated in AFFiRiS 002
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent signed and dated by patient and caregiver

          -  Patients having participated in AFF002 and having received at least 1 vaccination with
             AFFITOPE AD02

          -  Availability of a partner/caregiver knowing the patient and being able to accompany
             the patient to the visits

        Exclusion Criteria:

          -  Patients having received no vaccination with AFFITOPE AD02

          -  History of questionable compliance to visit schedule, patients not expected to finish
             the clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margot Schmitz, MD Univ. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ordination Schmitz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ordination Schmitz</name>
      <address>
        <city>Vienna</city>
        <zip>1010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2008</study_first_submitted>
  <study_first_submitted_qc>July 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2008</study_first_posted>
  <last_update_submitted>May 26, 2010</last_update_submitted>
  <last_update_submitted_qc>May 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Affiris AG</name_title>
  </responsible_party>
  <keyword>Alzheimer</keyword>
  <keyword>Morbus Alzheimer</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Alzheimer Vaccine</keyword>
  <keyword>A-beta immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

